RxDoctor Payments Data

Mananya Satayaprasert, MD

Neurology · Santa Barbara, CANPI 1326226887

Payments from drug & device makers

$12,303in general payments, 2019–2025

Across 615 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$906
  • UCB, Inc.$856
  • Biogen$734
  • EMD Serono, Inc.$541
  • Pfizer$446
  • plus $6K from 51 others

What the payments were for

  • Speaking & faculty fees$430%
  • Food & beverage$12,12199%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,303 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$210,855
Medicare patients
376
Services billed
15,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4676$337,628
Radicava OrsEdaravone20$279,110
RadicavaEdaravone13$161,051
QuliptaAtogepant18$24,636
Aimovig AutoinjectorErenumab-Aooe27$24,215
Emgality PenGalcanezumab-Gnlm14$14,482
Mycophenolate Mofetil20$6,573
Carbidopa-LevodopaCarbidopa/Levodopa112$5,528
Gabapentin239$5,134
Lacosamide16$3,271
Memantine Hcl67$1,888
Pregabalin51$1,782
Donepezil Hcl136$1,774
Levetiracetam53$1,444
Duloxetine Hcl17$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$73$337,62876 claims
AbbVieQulipta$3,031$24,63618 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$245$6,57320 claims
Upsher-smith Laboratories LLCTopiramate$15$36331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →